Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:59:56 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:NVCR - NOVOCURE LTD - http://www.novocure.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVCR - Q0.212.75·12.979.912.80+0.1651.31,074.013,14211,06012.81  13.02  12.72583.60  10.8716:19:28Apr 2415 min RT 2¢

Recent Trades - Last 10 of 11060
Time ETExPriceChangeVolume
16:19:28Q12.800.16518,424
16:16:09Q12.800.16515
16:08:28Q12.800.1651
16:07:56Q12.800.1651
16:05:49Q12.770.1351
16:01:54Q12.800.165137
16:01:51Q12.800.165622
16:01:31Q12.800.1659,785
16:01:13Q12.800.165376
16:01:09Q12.800.16559,432

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 10:45U:NVCRNews ReleaseResults of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
2024-04-05 07:00U:NVCRNews ReleaseNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
2024-04-01 07:00U:NVCRNews ReleaseNovocure to Report First Quarter 2024 Financial Results
2024-03-27 07:00U:NVCRNews ReleaseMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
2024-03-11 07:00U:NVCRNews ReleaseINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
2024-01-18 07:00U:NVCRNews ReleaseNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
2024-01-09 07:00U:NVCRNews ReleaseNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
2024-01-08 07:00U:NVCRNews ReleaseNovocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
2024-01-04 16:05U:NVCRNews ReleaseNovocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
2023-12-27 07:00U:NVCRNews ReleaseNovocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-11-28 07:30U:NVCRNews ReleaseNovocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
2023-11-21 07:00U:NVCRNews ReleaseNovocure to Participate in 35th Annual Piper Sandler Healthcare Conference
2023-11-10 08:00U:NVCRNews ReleaseNovocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
2023-10-26 07:00U:NVCRNews ReleaseNovocure Reports Third Quarter 2023 Financial Results
2023-10-15 18:05U:NVCRNews ReleaseNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
2023-10-12 08:00U:NVCRNews ReleaseNovocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
2023-10-02 07:00U:NVCRNews ReleaseNovocure to Report Third Quarter 2023 Financial Results
2023-09-29 17:00U:NVCRNews ReleaseNovocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
2023-09-08 16:01U:NVCRNews ReleaseNovocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
2023-08-29 18:31U:NVCRNews ReleaseNovocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies